Prognostic implications of response to neoadjuvant chemotherapy in breast cancer subtypes.

IF 1.9 4区医学 Q3 INFECTIOUS DISEASES

Journal of Chemotherapy Pub Date : 2025-02-01 Epub Date: 2024-02-13 DOI:10.1080/1120009X.2024.2314830

Anil Yıldiz, Ahmet Bilici, Ozgur Acikgoz, Jamshid Hamdard, Pelin Basim, Tansel Cakir, Asli Cakir, Omer Fatih Olmez, Cem Gezen, Ozcan Yildiz

{"title":"Prognostic implications of response to neoadjuvant chemotherapy in breast cancer subtypes.","authors":"Anil Yıldiz, Ahmet Bilici, Ozgur Acikgoz, Jamshid Hamdard, Pelin Basim, Tansel Cakir, Asli Cakir, Omer Fatih Olmez, Cem Gezen, Ozcan Yildiz","doi":"10.1080/1120009X.2024.2314830","DOIUrl":null,"url":null,"abstract":"The current study was designed to assess the response to treatment, as well as clinical and survival outcomes, across different breast cancer subtypes in patients who underwent neoadjuvant chemotherapy (NAC). From 2014 to 2019, a total of 139 patients who were histologically confirmed to have breast cancer, underwent NAC, and subsequently received breast and axillary surgery, were retrospectively included in this study. The rates of pathological complete response (pCR) to NAC were significantly higher for HER2-positive and triple-negative subtypes than for luminal A and HER2-negative subtypes (p = 0.013). Multivariate analysis for disease-free survival (DFS) revealed that tumour grade and the presence of pCR were independent prognostic factors. The presence or absence of a pCR with NAC was an independent prognostic indicator in the multivariate analysis for overall survival (OS). Lastly, achieving a pCR was independently predicted by 18F-FDG PET/CT findings, the HER2-positive subtype, and the triple-negative subtype. Despite the inherent methodological limitations, our findings underscore the significance of identifying predictive markers to tailor NAC plans, with the aim of improving survival outcomes.","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"60-68"},"PeriodicalIF":1.9000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Chemotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/1120009X.2024.2314830","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/2/13 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

Abstract

The current study was designed to assess the response to treatment, as well as clinical and survival outcomes, across different breast cancer subtypes in patients who underwent neoadjuvant chemotherapy (NAC). From 2014 to 2019, a total of 139 patients who were histologically confirmed to have breast cancer, underwent NAC, and subsequently received breast and axillary surgery, were retrospectively included in this study. The rates of pathological complete response (pCR) to NAC were significantly higher for HER2-positive and triple-negative subtypes than for luminal A and HER2-negative subtypes (p = 0.013). Multivariate analysis for disease-free survival (DFS) revealed that tumour grade and the presence of pCR were independent prognostic factors. The presence or absence of a pCR with NAC was an independent prognostic indicator in the multivariate analysis for overall survival (OS). Lastly, achieving a pCR was independently predicted by ¹⁸F-FDG PET/CT findings, the HER2-positive subtype, and the triple-negative subtype. Despite the inherent methodological limitations, our findings underscore the significance of identifying predictive markers to tailor NAC plans, with the aim of improving survival outcomes.

查看原文本刊更多论文

乳腺癌亚型对新辅助化疗反应的预后影响。

本研究旨在评估接受新辅助化疗（NAC）的不同亚型乳腺癌患者对治疗的反应以及临床和生存结果。从2014年到2019年，共有139名经组织学确诊为乳腺癌的患者接受了新辅助化疗，并在随后接受了乳腺和腋窝手术，这些患者被回顾性地纳入了这项研究。HER2阳性和三阴性亚型患者对NAC的病理完全反应（pCR）率明显高于管腔A型和HER2阴性亚型患者（p = 0.013）。无病生存期（DFS）多变量分析显示，肿瘤分级和是否存在 pCR 是独立的预后因素。在总生存期（OS）的多变量分析中，NAC是否存在pCR是一个独立的预后指标。最后，18F-FDG PET/CT 结果、HER2 阳性亚型和三阴性亚型也是预测获得 pCR 的独立因素。尽管存在固有的方法学局限性，但我们的研究结果凸显了确定预测标志物以定制 NAC 计划的重要性，其目的是改善生存预后。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Chemotherapy 医学-药学

CiteScore

3.70

自引率

0.00%

发文量

144

审稿时长

6-12 weeks

期刊介绍： The Journal of Chemotherapy is an international multidisciplinary journal committed to the rapid publication of high quality, peer-reviewed, original research on all aspects of antimicrobial and antitumor chemotherapy. The Journal publishes original experimental and clinical research articles, state-of-the-art reviews, brief communications and letters on all aspects of chemotherapy, providing coverage of the pathogenesis, diagnosis, treatment, and control of infection, as well as the use of anticancer and immunomodulating drugs. Specific areas of focus include, but are not limited to: · Antibacterial, antiviral, antifungal, antiparasitic, and antiprotozoal agents; · Anticancer classical and targeted chemotherapeutic agents, biological agents, hormonal drugs, immunomodulatory drugs, cell therapy and gene therapy; · Pharmacokinetic and pharmacodynamic properties of antimicrobial and anticancer agents; · The efficacy, safety and toxicology profiles of antimicrobial and anticancer drugs; · Drug interactions in single or combined applications; · Drug resistance to antimicrobial and anticancer drugs; · Research and development of novel antimicrobial and anticancer drugs, including preclinical, translational and clinical research; · Biomarkers of sensitivity and/or resistance for antimicrobial and anticancer drugs; · Pharmacogenetics and pharmacogenomics; · Precision medicine in infectious disease therapy and in cancer therapy; · Pharmacoeconomics of antimicrobial and anticancer therapies and the implications to patients, health services, and the pharmaceutical industry.